In this article, we review why patients may fail medical therapy for benign prostatic hyperplasia (BPH) and by doing so, gain a better understanding of the disease process and how to optimize the care of these patients.
A growing body of literature has attempted to better characterize the various mechanisms by which patients develop BPH as well as identify predictors of disease progression and treatment failure. BPH is a heterogenous disease process. A more personalized approach to treatment, including patient selection for medical or surgical management, would allow us to optimize patient care.
Current urology reports. 2019 Jun 06*** epublish ***
Zeynep G Gul, Steven A Kaplan
Department of Urology, Icahn School of medicine at Mount Sinai, 5 East 98th Street, 6th floor, New York, NY, 10029-6574, USA., Department of Urology, Icahn School of medicine at Mount Sinai, 5 East 98th Street, 6th floor, New York, NY, 10029-6574, USA. .